vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and M/I HOMES, INC. (MHO). Click either name above to swap in a different company.
M/I HOMES, INC. is the larger business by last-quarter revenue ($1.1B vs $598.7M, roughly 1.9× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 5.6%, a 35.3% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs -4.8%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $-13.0M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 4.7%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
M/I Homes, Inc. is a leading U.S. residential construction company that designs, builds and sells single-family homes, townhomes and duplexes across multiple U.S. states. It caters to entry-level, move-up and luxury homebuyers, offering energy-efficient designs, flexible floor plans and personalized customization options.
EXEL vs MHO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $1.1B |
| Net Profit | $244.5M | $64.0M |
| Gross Margin | 95.6% | 17.4% |
| Operating Margin | 39.3% | 6.5% |
| Net Margin | 40.8% | 5.6% |
| Revenue YoY | 5.6% | -4.8% |
| Net Profit YoY | 74.8% | -52.1% |
| EPS (diluted) | $0.89 | $2.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $1.1B | ||
| Q3 25 | $568.3M | $1.1B | ||
| Q2 25 | $555.4M | $1.2B | ||
| Q1 25 | $566.8M | $976.1M | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $539.5M | $1.1B | ||
| Q2 24 | $637.2M | $1.1B |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $64.0M | ||
| Q3 25 | $184.8M | $106.5M | ||
| Q2 25 | $159.6M | $121.2M | ||
| Q1 25 | $139.9M | $111.2M | ||
| Q4 24 | — | $133.5M | ||
| Q3 24 | $118.0M | $145.4M | ||
| Q2 24 | $226.1M | $146.7M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 17.4% | ||
| Q3 25 | 96.6% | 24.5% | ||
| Q2 25 | 96.5% | 24.7% | ||
| Q1 25 | 96.5% | 25.9% | ||
| Q4 24 | — | 24.6% | ||
| Q3 24 | 96.8% | 27.1% | ||
| Q2 24 | 97.2% | 27.9% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 6.5% | ||
| Q3 25 | 37.6% | 12.0% | ||
| Q2 25 | 33.6% | 13.4% | ||
| Q1 25 | 28.8% | 14.4% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | 25.2% | 15.9% | ||
| Q2 24 | 43.3% | 16.8% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 5.6% | ||
| Q3 25 | 32.5% | 9.4% | ||
| Q2 25 | 28.7% | 10.4% | ||
| Q1 25 | 24.7% | 11.4% | ||
| Q4 24 | — | 11.1% | ||
| Q3 24 | 21.9% | 12.7% | ||
| Q2 24 | 35.5% | 13.2% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $2.42 | ||
| Q3 25 | $0.65 | $3.92 | ||
| Q2 25 | $0.55 | $4.42 | ||
| Q1 25 | $0.47 | $3.98 | ||
| Q4 24 | — | $4.71 | ||
| Q3 24 | $0.40 | $5.10 | ||
| Q2 24 | $0.77 | $5.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $3.2B |
| Total Assets | $2.8B | $4.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | — | ||
| Q3 25 | $791.1M | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.0B | — |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $3.2B | ||
| Q3 25 | $2.0B | $3.1B | ||
| Q2 25 | $2.1B | $3.1B | ||
| Q1 25 | $2.2B | $3.0B | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | $2.3B | $2.8B | ||
| Q2 24 | $2.1B | $2.7B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $4.8B | ||
| Q3 25 | $2.7B | $4.8B | ||
| Q2 25 | $2.8B | $4.7B | ||
| Q1 25 | $2.9B | $4.6B | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | $3.0B | $4.5B | ||
| Q2 24 | $2.8B | $4.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $-8.7M |
| Free Cash FlowOCF − Capex | $332.4M | $-13.0M |
| FCF MarginFCF / Revenue | 55.5% | -1.1% |
| Capex IntensityCapex / Revenue | 0.2% | 0.4% |
| Cash ConversionOCF / Net Profit | 1.36× | -0.14× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $127.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $-8.7M | ||
| Q3 25 | $49.0M | $43.4M | ||
| Q2 25 | $211.4M | $37.8M | ||
| Q1 25 | $240.3M | $64.9M | ||
| Q4 24 | — | $104.4M | ||
| Q3 24 | $271.3M | $-67.9M | ||
| Q2 24 | $119.5M | $27.5M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $-13.0M | ||
| Q3 25 | $46.2M | $42.0M | ||
| Q2 25 | $208.5M | $35.1M | ||
| Q1 25 | $236.3M | $63.5M | ||
| Q4 24 | — | $102.3M | ||
| Q3 24 | $263.1M | $-68.5M | ||
| Q2 24 | $113.0M | $22.0M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | -1.1% | ||
| Q3 25 | 8.1% | 3.7% | ||
| Q2 25 | 37.5% | 3.0% | ||
| Q1 25 | 41.7% | 6.5% | ||
| Q4 24 | — | 8.5% | ||
| Q3 24 | 48.8% | -6.0% | ||
| Q2 24 | 17.7% | 2.0% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 0.4% | ||
| Q3 25 | 0.5% | 0.1% | ||
| Q2 25 | 0.5% | 0.2% | ||
| Q1 25 | 0.7% | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | 1.5% | 0.1% | ||
| Q2 24 | 1.0% | 0.5% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | -0.14× | ||
| Q3 25 | 0.27× | 0.41× | ||
| Q2 25 | 1.32× | 0.31× | ||
| Q1 25 | 1.72× | 0.58× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | 2.30× | -0.47× | ||
| Q2 24 | 0.53× | 0.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
MHO
| Southern Homebuilding | $615.6M | 54% |
| Northern Homebuilding | $503.9M | 44% |
| Financial Service | $27.8M | 2% |
| Land | $4.7M | 0% |
